The process of producing the world’s first commercially available heart transplant is almost complete.
The Italian company O2 Chemical is making the heart, called the O2-Pelvic Heart, and hopes to sell it in the US in the next few years.
The heart is being made in a lab in Milan, and the production is expected to begin in 2019.
“The heart has to be ready for the surgery at least a month before surgery,” said Dr. Giovanni Pellegrini, head of the Oesti-Pelo laboratory.
The heart, made by adding a mix of different substances, is made by soaking the skin of the animal, adding some blood and then adding chemicals to make it look like blood.
The mixture is then put in an oxygen tank and heated to about 3,000 degrees Celsius (6,000 Fahrenheit) to make the tissue grow.
The cells, which are made from human cells, then take about 15 days to form and the heart is attached to the animal’s chest by a thin tube.
When the heart grows and the animal begins to move, the heart begins to pump blood, but only after it is attached by a tube.
Once attached, the patient can no longer breathe and the blood pressure drops, and then the heart stops pumping.
O2 has been working on the project since 2007, but its first operation took place only last year, according to Pellegretti.
“We had an operation with the Oasis in the winter of 2017 and then we had a year without operations,” he said.
“It was not good enough for us.”
The heart is made in two stages: first, a mixture of substances, such as red blood cells, is heated to at least 500 degrees Celsius, which is around 3,300 Fahrenheit, and is then added to a tank.
The second stage is to make cells of various colors and proteins, then wait for them to grow.
Once the cells are ready, the animal is moved to a room filled with air, then heated to 500 degrees C, and left to cool down.
Once cooled, the cells and proteins are extracted and dried.
The team is working on a different type of heart, which could be used in hospitals and medical settings.
The next step will be to produce the heart for the human population.
The company has not yet decided on the price of the heart.
The company hopes to make at least $100,000 for the heart and the price tag could range from $2,000 to $10,000, Pellegresi said.
“It’s a big question mark,” he added.
“The price will depend on the number of patients that need it, and whether the market can support the cost.”